Improving in vivo assays in snake venom and antivenom research: A community discussion

Amy Marriott; Nick Casewell; Elliot Lilley; José María Gutiérrez; Stuart Ainsworth

doi:10.12688/f1000research.148223.1

Improving in vivo assays in snake venom and antivenom research: A community discussion

Amy Marriott, Nick Casewell, Elliot Lilley, José María Gutiérrez, Stuart Ainsworth

Tropical Disease Biology

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

On the 26th January 2023, a free to attend, ‘improving in vivo snake venom research: a community discussion’ meeting was held virtually. This webinar brought together researchers from around the world to discuss current neutralisation of venom lethality mouse assays that are used globally to assess the efficacy of therapies for snakebite envenoming. The assay’s strengths and weaknesses were highlighted, and we discussed what improvements could be made to refine and reduce animal testing, whilst supporting preclinical antivenom and drug discovery for snakebite envenoming. This report summarises the issues highlighted, the discussions held, with additional commentary on key perspectives provided by the authors.

Original language	English
Article number	192
Journal	F1000Research
Volume	13
DOIs	https://doi.org/10.12688/f1000research.148223.1
Publication status	Published - 15 Mar 2024

Keywords

3Rs
Antivenom
Lethality
NAMs
Preclinical assays
Venom

Access to Document

10.12688/f1000research.148223.1Licence: CC BY

SnakeVenomF1000Researchpaper amy marriottFinal published version, 371 KBLicence: CC BY

Cite this

@article{ba77e507fa0b436792089801586f6cfd,

title = "Improving in vivo assays in snake venom and antivenom research: A community discussion",

abstract = "On the 26th January 2023, a free to attend, {\textquoteleft}improving in vivo snake venom research: a community discussion{\textquoteright} meeting was held virtually. This webinar brought together researchers from around the world to discuss current neutralisation of venom lethality mouse assays that are used globally to assess the efficacy of therapies for snakebite envenoming. The assay{\textquoteright}s strengths and weaknesses were highlighted, and we discussed what improvements could be made to refine and reduce animal testing, whilst supporting preclinical antivenom and drug discovery for snakebite envenoming. This report summarises the issues highlighted, the discussions held, with additional commentary on key perspectives provided by the authors.",

keywords = "3Rs, Antivenom, Lethality, NAMs, Preclinical assays, Venom",

author = "Amy Marriott and Nick Casewell and Elliot Lilley and Guti{\'e}rrez, \{Jos{\'e} Mar{\'i}a\} and Stuart Ainsworth",

year = "2024",

month = mar,

day = "15",

doi = "10.12688/f1000research.148223.1",

language = "English",

volume = "13",

journal = "F1000Research",

issn = "2046-1402",

publisher = "F1000 Research Ltd",

}

TY - JOUR

T1 - Improving in vivo assays in snake venom and antivenom research: A community discussion

AU - Marriott, Amy

AU - Casewell, Nick

AU - Lilley, Elliot

AU - Gutiérrez, José María

AU - Ainsworth, Stuart

PY - 2024/3/15

Y1 - 2024/3/15

N2 - On the 26th January 2023, a free to attend, ‘improving in vivo snake venom research: a community discussion’ meeting was held virtually. This webinar brought together researchers from around the world to discuss current neutralisation of venom lethality mouse assays that are used globally to assess the efficacy of therapies for snakebite envenoming. The assay’s strengths and weaknesses were highlighted, and we discussed what improvements could be made to refine and reduce animal testing, whilst supporting preclinical antivenom and drug discovery for snakebite envenoming. This report summarises the issues highlighted, the discussions held, with additional commentary on key perspectives provided by the authors.

AB - On the 26th January 2023, a free to attend, ‘improving in vivo snake venom research: a community discussion’ meeting was held virtually. This webinar brought together researchers from around the world to discuss current neutralisation of venom lethality mouse assays that are used globally to assess the efficacy of therapies for snakebite envenoming. The assay’s strengths and weaknesses were highlighted, and we discussed what improvements could be made to refine and reduce animal testing, whilst supporting preclinical antivenom and drug discovery for snakebite envenoming. This report summarises the issues highlighted, the discussions held, with additional commentary on key perspectives provided by the authors.

KW - 3Rs

KW - Antivenom

KW - Lethality

KW - NAMs

KW - Preclinical assays

KW - Venom

U2 - 10.12688/f1000research.148223.1

DO - 10.12688/f1000research.148223.1

M3 - Article

SN - 2046-1402

VL - 13

JO - F1000Research

JF - F1000Research

M1 - 192

ER -

Improving in vivo assays in snake venom and antivenom research: A community discussion

Abstract

Keywords

Access to Document

Fingerprint

Cite this